ARCH Venture Partners
Edit

ARCH Venture Partners

https://www.archventure.com
Last activity: 31.03.2025
Active
Invests in categories: HealthTechPlatformDrugTechnologyDevelopmentBioTechProductMedtechResearchCare
Early stage venture firm focused on life science discoveries to prevent, detect and cure disease.
News
70
Portfolio
213
Persons
4
Mentions
169
Location: United States, Illinois, Chicago
Employees: 11-50
Founded date: 1986
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A; Series B; Series C; IPO; Grant

Portfolio 213

DateNameWebsiteTotal RaisedLocation
29.12.2024Vesalius T...vesaliustx.com$75MUnited Sta...
29.12.2024Moleculent...moleculent.com$26MSweden, St...
29.12.2024City Thera...citytx.com--
29.12.2024Arsenal Bi...arsenalbio.com$410MUnited Sta...
29.12.2024Parabilis ...parabilismed.com-United Sta...
16.09.2024Gate Biosc...gatebio.com$60MUnited Sta...
16.09.2024Enumerixenumerix.com-United Sta...
16.09.2024Seaport Th...seaporttx.com$225MUnited Sta...
16.09.2024Mirador Th...miradortx.com-United Sta...
16.09.2024Metserametsera.com$505MUnited Sta...
Show more

Persons 4

DateFirst NameLast NameTitleLinkedInLocation
-KristinaBurowManaging D...linkedin.c...-
-KeithCrandellCo-founder...-
-RobertNelsenCo-founder...-
-SteveGillis, Ph...Managing D...linkedin.c...-

News 70

DateTitleDescription
27.02.2024Managing Director Kristina Burow named to STAT’s 2024 STATUS list alongside other top leaders shaping the industry-
01.11.2023With ARCH funding, Gate Biosciences finds new way to attack diseases-
21.09.2023Four ARCH-backed companies named to Endpoints 11 list of most exciting biotech startups in 2023-
14.07.2023ARCH Venture Partners Announces Appointment of Kent Rogers as Venture Partner-
25.05.2023ARCH Venture Partners Announces Appointment of Kevin Hrusovsky as Venture Partner-
23.05.2023ARCH Venture Partners Announces Appointment of Jami Rubin as Venture Partner-
25.04.2023ARCH leads Series A for Orbital, supporting research to unleash full potential of RNA medicines-
06.04.2023ARCH Venture Partners Announces Appointment of Brian Cuneo as Senior Partner-
07.03.2023ARCH leads Volastra $60 million financing round-
27.01.2023The New York Times profiled ARCH-backed Paradigm, which aims to simplify clinical trials-
Show more

Mentions in press and media 169

DateTitleDescription
31.03.2025Alphabet-Backed Isomorphic Labs Raises $600M For AI Drug Development3 Shares Email Facebook Twitter LinkedIn Google spinoff Isomorphic Labs raised $600 million in its first external funding round as the company looks to apply artificial intelligence to the drug development process. The new round was led by ...
23.01.2025MGX’s AI Role In The US Grows2 Shares Email Facebook Twitter LinkedIn While most of the talk about the White House’s new Stargate Project centered on the three big tech names — OpenAI, SoftBank and Oracle — Abu Dhabi-based investment firm MGX also is poised to play a b...
15.01.2025Be Bio Closes $92M Series C FinancingBe Bio, a Cambridge, MA-based company which specializes in B Cell Medicines (BCMs), raised $92M in Series C funding. The round was led by Nextech with existing investors including ARCH Venture Partners, Atlas Venture, RA Capital Management,...
15.01.2025RhyGaze raises CHF 86 million to advance gene therapy for retinal diseases RhyGaze was founded on intellectual property exclusively licensed to the company by the Institute of Molecular and Clinical Ophthalmology Basel (IOB), a scientific institute led by Director Botond Roska, who is a scientific co-founder of R...
15.01.2025Colossal Raises $200M in Series C FundingColossal Biosciences, a Dallas, TX-based de-extinction company, raised $200M in Series C Funding. Backers included TWG Global. Other investors included USIT, Animal Capital, Breyer Capital, At One Ventures, In-Q-Tel, BOLD Capital, Peak 6, D...
13.01.2025RhyGaze: $86 Million (Series A) Raised To Develop Gene Therapies For Retinal DiseasesRhyGaze, a biotechnology company based in Basel, Switzerland, and Philadelphia, PA, announced that it has raised a Series A funding round of $86 million. The funding round was led by GV (Google Ventures), alongside Arch Venture Partners, F-...
13.01.2025RhyGaze Closes USD 86M Series A FundingRhyGaze, a Basel, Switzerland- and Philadelphia, PA-based biotechnology company developing gene therapies for retinal diseases, raised USD 86M in Series A funding. The round was led by GV (Google Ventures), alongside Arch Venture Partners, ...
08.01.2025Third Rock-backed Maze Therapeutics reveals profit in US IPO filingThird Rock-backed Maze Therapeutics reveals profit in US IPO filing By ReutersJanuary 7, 202511:00 PM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link The Nasdaq logo is displayed at the Nasdaq Mark...
19.12.2024bit.bio raises $30 Million led by M&G Investmentsbit.bio raises $30 Million led by M&G Investments to focus on tools for the research, drug discovery and cell therapy markets. Jonathan Milner appointed Interim CEO; Mark Kotter assumes Vice Chairman role as Company expands Board with d...
14.12.2024The Rise of nChroma Bio: A New Dawn in Genetic MedicineIn the world of biotechnology, mergers and funding are the lifeblood of innovation. Recently, two companies, Chroma Medicine and Nvelop Therapeutics, joined forces to create nChroma Bio. This new entity is set to redefine the landscape of g...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In